OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) is Far More than Meets the Eye

Following our enormous win the junior gold mining space earlier this month, we are now ready to turn our attention to another market segment that offers the potential for home runs and grand slams on a regular basis: biotechnology. Today’s research focus is OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP). And, fortunately, it’s not a difficult study: there’s […]

OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) making strides in the $7.1 billion prostate cancer treatment space

OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP), a biopharmaceutical company making strides in the $7.1 billion prostate cancer treatment space, has continued to show very strong action on the charts so far in 2017, up more than 100% in a little over five weeks of action. We have been closely watching the company this year, and can offer […]

OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) Provides Positive Update on ProscaVax Data

OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) has been one of our favorite new players in the $7.1 billion prostate cancer treatment market. The company just put out a new press release summarizing data that makes a strong case in the preparation of a coming Phase II trial of ProscaVax, which is OncBioMune’s lead pipeline asset. As noted […]

OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) Presents Interesting Picture as a Bite-Size Buyout Candidate

OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) is in an interesting phase of its existence. The company just solidified its sense of credibility in the space with a recent announcement of a productive meeting with top staffing scientists at the host hospital of the Company’s upcoming Phase 2 trial of ProscaVax for prostate cancer. That represents the first […]